Tuesday, September 05, 2023
Mainz Biomed N.V., a company specializing in molecular genetics diagnostics for early cancer detection, has announced a strategic partnership with Ärztliches Labor Dr. Buhlmann to bolster its presence in the German market.
This partnership is aimed at providing Mainz Biomed with greater access to and potential expansion within Germany's private health insurance (PHI) sector, where its ColoAlert® test for colorectal cancer (CRC) is already reimbursed.
Founded in 2006 and led by Dr. Annette Buhlmann, a seasoned expert with over 25 years of experience in laboratory medicine, Ärztliches Labor Dr. Buhlmann is renowned for its proficiency in PCR-based analysis. Their services encompass molecular diagnostics, genetics, HLA testing, and infectious disease assessments, catering to a diverse clientele spanning both statutory and private insurance sectors.
With an estimated 10.5% of Germany's population (approximately 8.7 million individuals) covered by PHI, as per 2022 estimates from the Association of Substitute Health Insurance Funds (vdek), this partnership opens up a significant market channel for Mainz Biomed. Furthermore, a substantial portion of these PHI beneficiaries falls within the critical 50-74 age group, the primary target demographic for CRC screening in Germany.
Darin Leigh, Chief Commercial Officer of Mainz Biomed, expressed optimism about the collaboration, emphasizing their dedication to integrating ColoAlert into Germany's statutory health insurance reimbursement framework. He foresees that partnering with Dr. Buhlmann's laboratory will expedite the adoption of ColoAlert in Germany, aligning with their mission to advance early CRC detection globally.
Dr. Buhlmann also conveyed her enthusiasm, highlighting ColoAlert's innovative approach in identifying DNA biomarkers for enhanced CRC testing compared to traditional Fecal Occult Blood Tests (iFOBT). She emphasized the significance of offering improved access to alternative testing options for early CRC detection, not only in Germany but also across European markets, through collaborations with physicians, health authorities, and private clients.